Senzime AB (6YC) AI Stock Analysis

Senzime AB

(Frankfurt:6YC)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring Sensor RevenueThe high recurring share links revenue to the installed system base and procedure activity, supporting visibility beyond one-time monitor sales. Strong sensor growth also indicates increasing utilization and creates an attractive consumables-led model that can compound as more systems are deployed.

Negative Factors

Deep Ongoing LossesThe company remains far from sustainable profitability despite revenue growth and better gross margin. Large operating and net losses indicate that the current cost structure still exceeds the revenue base, leaving execution dependent on further scale, continued expense control, and successful margin conversion.

Senzime AB (6YC) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 36.98M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -5.5
Beta (1Y): 1.09
Revenue Growth: 21.15%
EPS Growth: 26.19%
Country: Germany
Employees: 59
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Senzime AB Business Overview & Revenue Model

Company Description

Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europ...

Senzime AB Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:19.83%|Next Earnings Date:Feb 17, 2027

Earnings Call SentimentPositive

The call was strongly constructive. Senzime reported renewed growth, 43% sensor growth, a record 74% gross margin, lower operating expenses, materially improved EBITDA and cash flow, secured financing, and a reiterated target of positive cash flow within Q4. The main challenges were delayed U.S. deal closures, weaker monitor sales, no Q3 TetraGraph-as-a-Service contracts, ongoing market adoption work, and pending South Korean regulatory approval.

Positive Updates

Return to Broad-Based Growth

Senzime reported 14% growth in Q3 and said it grew in all regions. Q3 sales were SEK 30.1 million, with the U.S. remaining the main driver while Asian and European markets were also beginning to take off.

Negative Updates

Monitor Sales Remain Weak

Monitor sales had a tougher year, particularly in the U.S., and offset part of the 43% growth in sensor sales. Management said it is taking longer to close monitor deals.

Company Guidance

Management reiterated that it is “on path to reach positive cash flow within the fourth quarter,” clarifying that this means “November and December or November or we'll see what it is,” and said this is “the first step”; it is working to drive gross margin “to be in excess of 70%,” expects “70% to 80% of our business” to be recurring revenues, with this “over time” potentially “even higher,” and said “about probably more than 50% of the business over the next 10 years is going to be OEMs”; TetraGraph-as-a-Service has “some Q4 pipeline,” the Philips projects are “progressing as planned” with no market-launch timing disclosed, and South Korea has “a couple of months left” in regulatory submission mode.

Senzime AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:6YC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:PAX	60Neutral	SEK 1.54B	-303.85	-1.22%	―	34.05%	-144.96%
SE:BACTI.B	53Neutral	SEK 560.70M	88.89	1.93%	―	-0.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SEDANA	49Neutral	SEK 926.81M	-26.86	-3.88%	―	0.42%	15.03%
SE:ACARIX	33Underperform	SEK 223.04M	-5.29	-100.09%	―	65.82%	41.28%
SE:SCIB	30Underperform	SEK 174.38M	-0.78	-303.61%	―	51.21%	42.24%

* Healthcare Sector Average

Performance Comparison

DE:6YC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:6YC	Senzime AB	0.29	-0.19	-39.08%
SE:PAX	Paxman AB	66.30	-1.10	-1.63%
SE:SCIB	SciBase Holding AB	12.35	-13.24	-51.74%
SE:BACTI.B	Bactiguard Holding AB	16.00	-1.00	-5.88%
SE:ACARIX	Acarix AB	0.18	-0.10	-35.61%
SE:SEDANA	Sedana Medical AB	9.33	-0.83	-8.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Senzime AB AI Stock Analysis